About this document
Efficacy of Trastuzumab Deruxtecan in HER2+ Breast Cancer by MUHAMMAD ARMISH MEHDI is a document available to read on EtoBox.
The study evaluates the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine. In a phase 2 trial involving 184 patients, a 60.9% response rate was observed, with a median response duration of 14.8 months and a median progression-free survival of 16.4 months. Adverse events included interstitial lung disease in 13.6% of patients, highlighting the need for careful monitoring of pulmonary symptoms.
- Author
- MUHAMMAD ARMISH MEHDI
- Language
- EN